Leslie Stolz has a robust drug development background with roles in regulatory affairs, medical affairs and medical writing. Most recently, Leslie served as associate director of regulatory affairs at Shire, where she supported regulatory activities for biologic protein therapies for hereditary angioedema. She held a variety of roles at Dyax, which was acquired by Shire in 2016. Prior to that, Leslie worked in interventional cardiology programs at Boston Scientific. Leslie received a Ph.D. in molecular cancer biology from Duke University, and was a postdoctoral fellow at Wyeth’s Department of Cardiovascular and Metabolic Diseases Research.